MOTS-c vs SS-31
MOTS-c is a mitochondrial-derived peptide that signals systemically — it activates AMPK, improves insulin sensitivity, and enhances exercise capacity. SS-31 (elamipretide) is a mitochondrial-targeting peptide that binds cardiolipin on the inner mitochondrial membrane, preserving electron-transport-chain function and reducing oxidative damage. Same organelle, completely different mechanism.
MOTS-c is the metabolic-lever tool — insulin sensitivity, exercise response, AMPK activation. SS-31 is the structural mitochondrial tool — cardiolipin preservation, inner-membrane stabilization, oxidative stress buffering. Different questions, different tools. Many serious longevity protocols run both.
Contender A
MOTS-c
16-amino-acid peptide encoded within mitochondrial DNA — acts as a signaling hormone, activating AMPK, improving insulin sensitivity, and amplifying exercise response.
- Half-life
- ~5 hours
- Primary use
- Metabolic / insulin / exercise-response research
- Dose range
- 5-10 mg SubQ, 2-3x weekly
- Cost tier
- $$ · Moderate sourcing cost
Contender B
SS-31
Also: SS-31 (elamipretide)
Mitochondrial-targeting tetrapeptide — binds cardiolipin on the inner mitochondrial membrane, stabilizing ETC complexes and reducing ROS production at source.
- Half-life
- ~2-4 hours
- Primary use
- Mitochondrial-structural / cardio-protective research
- Dose range
- 1-5 mg SubQ daily
- Cost tier
- $$$ · High sourcing cost
Detailed Comparison
10 attributes side-by-side. Highlighted rows show where one tool has a clear structural edge.
| Attribute | MOTS-c | SS-31 (elamipretide) | Edge |
|---|---|---|---|
Mechanism class | Mitochondrial hormone (signaling) | Cardiolipin-binding (structural) | Tie |
Primary target | AMPK / insulin sensitivity | Inner mitochondrial membrane | Tie |
Half-life | ~5 hours | ~2-4 hours | A |
Evidence maturity | Experimental / early human | Phase 3 clinical (Barth syndrome, cardio) | SS-31 (elamipretide) |
Metabolic-lever effect | Strong | Mild (downstream of bioenergetics) | A |
Exercise-capacity signal | Strong | Strong (different mechanism) | Tie |
Cardiac-protection signal | Moderate | Strong (its lead indication) | SS-31 (elamipretide) |
Oxidative stress reduction | Indirect | Direct, at source | SS-31 (elamipretide) |
Research-sourcing cost | Moderate | Higher | A |
Stack compatibility with the other | High | High | Tie |
Practitioner Notes
Sourced from practitioner-validated protocols — not PubMed abstracts.
The common newcomer mistake is treating these as interchangeable 'mitochondrial peptides.' They aren't. MOTS-c behaves like a metabolic hormone — it hits AMPK, changes insulin sensitivity, amplifies the response to exercise. SS-31 doesn't do any of that — it parks on the cardiolipin on the inner mitochondrial membrane and physically stabilizes the electron transport chain.
In practitioner protocols we've audited, the two are stacked when the research budget and endpoint justify it. MOTS-c drives the upstream metabolic lever; SS-31 preserves the downstream machinery. Running MOTS-c alone in a protocol where mitochondrial structural integrity is the bottleneck leaves the oxidative-damage arm untouched. Running SS-31 alone in an insulin-resistance or exercise-performance protocol misses the AMPK arm.
SS-31 has the maturity advantage — it's in Phase 3 trials for Barth syndrome and cardiac indications, which means the pharmacokinetics and safety envelope are well-mapped. MOTS-c is still experimental-tier, and the human dose-response is less precisely characterized. Practitioners running MOTS-c typically start low (5 mg) and titrate based on insulin-sensitivity and fasting-glucose markers.
Cost asymmetry matters here. SS-31 daily gets expensive fast; MOTS-c's 2-3x weekly cadence keeps costs contained.
Stacking & Switching
Can these be combined? Should you switch from one to the other? Titration considerations.
Stack compatibility: See the “Stacks well” or “Stack compatibility” row in the comparison table above. When the edge column shows Tie, both compounds run together cleanly. When one compound dominates, check the protocol notes for the specific stacking pattern practitioners use.
Switching protocol: The general pattern across practitioner protocols: hold the current dose stable, introduce the new compound at its lowest titration step, run both for a 1-2 week cross-over window, then taper the original. Abrupt switches produce rebound effects as the original compound's steady state clears.
Half-life math: DoseCraft's PK-aware AI models half-life decay and stack overlap across every pairing above. The 20x20 interaction matrix flags contraindications automatically — no manual math, no overlapping-signal blindspots.
Frequently Asked Questions
Indexed for SERP FAQPage rich results.
Are MOTS-c and SS-31 the same class?
+
Both are called 'mitochondrial peptides' but they work completely differently. MOTS-c is a signaling hormone that changes metabolism; SS-31 is a structural peptide that binds inner-membrane cardiolipin.
Which is better for longevity?
+
Different angles. MOTS-c moves the metabolic lever (insulin, AMPK, exercise response). SS-31 preserves the mitochondrial structure that makes the metabolic lever work. Serious longevity protocols increasingly use both.
Is SS-31 the same as elamipretide?
+
Yes — SS-31 is the research name; elamipretide is the drug name. Stealth BioTherapeutics ran the Phase 3 program. Same molecule.
Does MOTS-c really come from mitochondrial DNA?
+
Yes. MOTS-c is encoded in the 12S rRNA region of mitochondrial DNA — one of a small class of mitochondrial-derived peptides (including humanin) that act as signaling molecules on the rest of the cell.
Can I take them together?
+
Yes. No mechanistic overlap — different targets, different pathways. The 20x20 interaction matrix we maintain flags no contraindication at research doses.
Related Comparisons
Longevity
NAD+ vs NMN
NAD+ is the whole molecule — the cellular cofactor every sirtuin and PARP needs. NMN (nicotinamide mononucleotide) is the direct biosynthetic precursor, one step upstream of NAD+. Oral NAD+ is poorly absorbed; injectable NAD+ bypasses the gut. Oral NMN is reasonably absorbed and converts to NAD+ intracellularly. Both pathways elevate intracellular NAD+ — the tradeoff is delivery practicality.
ReadLongevity
Epitalon vs Thymalin
Epitalon (also called Epithalon) is a synthetic tetrapeptide developed from pineal-gland extract. Thymalin is a polypeptide complex from thymus tissue. Both emerged from the Khavinson longevity research program in Soviet/Russian gerontology. Different organ sources, different mechanisms — pineal / circadian for Epitalon, thymic / immune for Thymalin.
ReadHealing
BPC-157 vs TB-500
BPC-157 is a pentadecapeptide derived from gastric juice with strong localized healing signals, especially in GI and tendon research. TB-500 is a fragment of Thymosin Beta-4 with systemic actin-binding activity driving cell migration, angiogenesis, and broad tissue recovery. Half-lives and delivery profiles are very different; so are their niches.
ReadTrack Your Protocol with PK-Aware AI
Compound choice is step one. DoseCraft models half-life decay, stack overlap, and titration paths across 90+ peptides — a pharmacokinetic reasoning layer on top of practitioner-validated protocols.
Track your protocol with PK-aware AI in DoseCraftResearch-only disclaimer: This comparison is for research and educational purposes only. Peptides referenced are sold for research use by third-party suppliers. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed physician before acting on any peptide protocol information.